Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Provide Karolinska Institutet with Technology for Disease Studies

NEW YORK, Feb. 8 (GenomeWeb News) - The Karolinska Institutet of Swedenhas teamed up with Affymetrix to study gene expression and DNA sequence variation in patients with a number of diseases, the two partners said today.


The agreement is part of Affy's translational medicine initiative. Karolinska Institutet, based in Stockholm, will have early access to new microarray technologies from Affymetrix, including the company's Mapping 100K array for high-density genome scans, and will be able to perform studies "at an acceptable cost," according to Jan Carlstedt-Duke, Karolinska's dean of research.


Further financial details of the alliance were not provided.


Over the next five years, Karolinska researchers plan to study gene expression and genetic variation in patients with atherosclerosis, breast cancer, rheumatoid arthritis, asthma, and dyslexia.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more